Loading...
11 bamlanivimab COVID-19 controlled studies,
6 RCTs
https://c19ly.com/meta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Chen (RCT) 74%
0.26 [0.09-0.75]
hosp.
5/309
9/143
Improvement, RR [CI] Treatment Control Gottlieb (RCT) 71%
0.29 [0.09-0.96]
hosp./ER
4/101
7/52
Gottlieb (RCT) 80%
0.20 [0.03-1.56]
hosp./ER
1/37
7/52
Gottlieb (RCT) 75%
0.25 [0.03-1.92]
hosp./ER
1/30
7/52
Gottlieb (RCT) 56%
0.44 [0.10-1.98]
hosp./ER
2/34
7/52
Gottlieb (RCT) 92%
0.08 [0.00-1.39]
hosp./ER
0/31
7/52
Lilly (DB RCT) 92%
0.08 [0.00-1.43]
death
0/511
4/258
Lilly (DB RCT) 87%
0.13 [0.05-0.40]
hosp./death
4/511
15/258
Webb 80%
0.20 [0.03-1.46]
death
1/479
57/5,536
Webb 53%
0.47 [0.31-0.72]
hosp.
22/479
538/5,536
Webb 27%
0.73 [0.65-0.82]
hosp./ER
65/479
1,018/5,536
Cooper 45%
0.55 [0.07-3.99]
death
1/473
33/8,534
Cooper 58%
0.42 [0.10-1.72]
ICU
2/473
85/8,534
Cooper 5%
0.95 [0.69-1.30]
hosp.
37/473
703/8,534
Cooper -17%
1.17 [0.59-2.32]
death
11/2,427
33/8,534
Cooper 9%
0.91 [0.57-1.45]
ICU
22/2,427
85/8,534
Cooper 28%
0.72 [0.61-0.86]
hosp.
144/2,427
703/8,534
Rubin 97%
0.03 [0.00-0.25]
death
1/191
10/1,066
Rubin 65%
0.35 [0.12-0.94]
hosp.
16/191
121/1,065
ACTIV-3/T.. (RCT) -100%
2.00 [0.69-5.83]
death
9/163
5/151
Bariola 67%
0.33 [0.10-1.01]
death
4/234
12/234
Bariola 64%
0.36 [0.20-0.61]
hosp./death
16/234
45/234
Bariola 61%
0.39 [0.22-0.70]
hosp.
15/234
39/234
Ganesh 74%
0.26 [0.05-1.20]
death
2/1,789
8/1,832
Ganesh 49%
0.51 [0.24-1.09]
ICU
10/1,789
20/1,832
Ganesh 37%
0.63 [0.43-0.91]
hosp.
44/1,789
72/1,832
Chew (RCT) 25%
0.75 [0.26-2.10]
hosp.
6/159
8/158
Chew (RCT) 52%
0.48 [0.09-2.49]
hosp.
2/48
4/46
Chew (RCT) -1%
1.01 [0.26-3.93]
hosp.
4/111
4/112
Chew (RCT) -14%
1.14 [0.00-455]
recov. time
48 (n)
46 (n)
Chew (RCT) -17%
1.17 [0.98-1.40]
recov. time
111 (n)
112 (n)
Chew (RCT) 26%
0.74 [0.62-0.90]
viral load
48 (n)
46 (n)
Chew (RCT) 35%
0.65 [0.40-1.04]
viral load
111 (n)
112 (n)
Lilly (RCT) 57%
0.43 [0.28-0.67]
symp. case
483 (n)
482 (n)
Lilly (RCT) 80%
0.20 [0.08-0.47]
symp. case
150 (n)
149 (n)
bamlanivimab COVID-19 outcomes c19ly.com Jan 18, 2022
Favors bamlanivimab
Favors control
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
WCH
and
FLCCC provide
treatment protocols.
Submit
